Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Recurrent Pleural Malignant Mesothelioma

Tundra lists 3 Recurrent Pleural Malignant Mesothelioma clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ACTIVE NOT RECRUITING

NCT02535312

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

This phase I/II trial studies the side effects and the best dose of methoxyamine when given together with cisplatin and pemetrexed disodium and to see how well it works in treating patients with solid tumors or mesothelioma that have spread to other places in the body and usually cannot be cured or controlled with standard treatment (advanced), or mesothelioma that does not respond to pemetrexed disodium and cisplatin or carboplatin (refractory). Methoxyamine may shrink the tumor and may also help cisplatin and pemetrexed disodium work better by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as cisplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving methoxyamine together with cisplatin and pemetrexed disodium may be a better treatment for solid tumors or mesothelioma than methoxyamine and pemetrexed disodium.

Gender: All

Ages: 18 Years - Any

Updated: 2026-04-09

9 states

Advanced Malignant Solid Neoplasm
Advanced Peritoneal Malignant Mesothelioma
Advanced Pleural Malignant Mesothelioma
+4
ACTIVE NOT RECRUITING

NCT03074513

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-11

1 state

Appendix Adenocarcinoma
Human Papillomavirus-Related Anal Squamous Cell Carcinoma
Human Papillomavirus-Related Cervical Squamous Cell Carcinoma
+18
ACTIVE NOT RECRUITING

NCT02399371

Pembrolizumab in Treating Patients With Malignant Mesothelioma

This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum). Monoclonal antibodies, such as pembrolizumab, work by blocking a protein called programmed cell death 1 (PD-1) which may stimulate an immune response and kill tumor cells.

Gender: All

Ages: 18 Years - Any

Updated: 2025-06-11

1 state

Biphasic Mesothelioma
Epithelioid Mesothelioma
Peritoneal Malignant Mesothelioma
+7